Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.
Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up. Steinberg MH, et al. Among authors: kutlar a. Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699. Am J Hematol. 2010. PMID: 20513116 Free PMC article. Clinical Trial.
Sickle cell disease telemedicine network for rural outreach.
Woods KF, Johnson JA, Kutlar A, Daitch L, Stachura ME. Woods KF, et al. Among authors: kutlar a. J Telemed Telecare. 2000;6(5):285-90. doi: 10.1258/1357633001935923. J Telemed Telecare. 2000. PMID: 11070590
Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M. Steinberg MH, et al. Among authors: kutlar a. JAMA. 2003 Apr 2;289(13):1645-51. doi: 10.1001/jama.289.13.1645. JAMA. 2003. PMID: 12672732 Clinical Trial.
Alpha Thalassemia is associated with decreased risk of abnormal transcranial Doppler ultrasonography in children with sickle cell anemia.
Hsu LL, Miller ST, Wright E, Kutlar A, McKie V, Wang W, Pegelow CH, Driscoll C, Hurlet A, Woods G, Elsas L, Embury S, Adams RJ; Stroke Prevention Trial (STOP) and the Cooperative Study of Sickle Cell Disease (CSSCD). Hsu LL, et al. Among authors: kutlar a. J Pediatr Hematol Oncol. 2003 Aug;25(8):622-8. doi: 10.1097/00043426-200308000-00007. J Pediatr Hematol Oncol. 2003. PMID: 12902915
Mortality in sickle cell patients on hydroxyurea therapy.
Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A. Bakanay SM, et al. Among authors: kutlar a. Blood. 2005 Jan 15;105(2):545-7. doi: 10.1182/blood-2004-01-0322. Epub 2004 Sep 28. Blood. 2005. PMID: 15454485 Free article.
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.
Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, Stocker JW; ICA-17043-05 Investigators. Ataga KI, et al. Among authors: kutlar a. Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11. Blood. 2008. PMID: 18192510 Free article. Clinical Trial.
Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions.
Fung EB, Harmatz PR, Milet M, Balasa V, Ballas SK, Casella JF, Hilliard L, Kutlar A, McClain KL, Olivieri NF, Porter JB, Vichinsky EP; Multi-Center Iron Overload Research Group. Fung EB, et al. Among authors: kutlar a. Transfusion. 2008 Sep;48(9):1971-80. doi: 10.1111/j.1537-2995.2008.01775.x. Epub 2008 May 29. Transfusion. 2008. PMID: 18513257 Free PMC article.
Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).
Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW; ICA-17043-10 Study Investigators. Ataga KI, et al. Among authors: kutlar a. Br J Haematol. 2011 Apr;153(1):92-104. doi: 10.1111/j.1365-2141.2010.08520.x. Epub 2011 Feb 17. Br J Haematol. 2011. PMID: 21323872 Free article. Clinical Trial.
266 results